Mulholland K, Hilton S, Adegbola R, Usen S, Oparaugo A, Omosigho C, Weber M, Palmer A, Schneider G, Jobe K, Lahai G, Jaffar S, Secka O, Lin K, Ethevenaux C, Greenwood B
Medical Research Council Laboratories, Fajara, The Gambia.
Lancet. 1997 Apr 26;349(9060):1191-7. doi: 10.1016/s0140-6736(96)09267-7.
In developing countries, pneumonia and meningitis due to Haemophilus influenzae type b (Hib) are common in children under age 12 months and the mortality from meningitis is high. Protein-polysaccharide conjugate vaccines have brought Hib disease under control in industrialised countries. We did a double-blind randomised trial in The Gambia to assess the efficacy of a Hib conjugate vaccine for the prevention of meningitis, pneumonia, and other invasive diseases due to Hib.
Between March, 1993, and October, 1995, 42,848 infants were randomly allocated the conjugate vaccine Hib polysaccharide tetanus protein (PRP-T) mixed with diphtheria-tetanus-pertussis vaccine (DTP), or DTP alone at age 2 months, 3 months, and 4 months. Children who presented with signs of invasive Hib were investigated by blood culture and, where appropriate, by lumbar puncture, chest radiograph, or percutaneous lung aspirate. Children were followed up for between 5 and 36 months.
The median ages at which children received the study vaccine were 11 weeks, 18 weeks, and 24 weeks. 83% of children enrolled received all three doses of vaccine. 17 cases of culture-positive Hib pneumonia, 28 of Hib meningitis, and five of other forms of invasive Hib disease were detected amongst the study children. The efficacy of the vaccine for the prevention of all invasive disease after three doses was 95% (PRP-T vaccinees 1, controls 19 [95% CI 67-100]), for the prevention of Hib pneumonia after two or three doses, 100% (vaccinees 0, controls 10 [55-100]), and for the prevention of radiologically defined pneumonia at any time after enrollment, 21.1% (PRP-T vaccinees 198, controls 251 [4.6-34.9]).
PRP-T conjugate Hib vaccine prevented most cases of meningitis and pneumonia due to Hib in Gambian infants. The reduction in the overall incidence of radiologically defined pneumonia in PRP-T vaccinees suggests that about 20% of episodes of pneumonia in young Gambian children are due to Hib. The introduction of Hib vaccines into developing countries should substantially reduce childhood mortality due to pneumonia and meningitis.
在发展中国家,b型流感嗜血杆菌(Hib)引起的肺炎和脑膜炎在12个月以下儿童中很常见,且脑膜炎死亡率很高。蛋白质-多糖结合疫苗已在工业化国家控制了Hib疾病。我们在冈比亚进行了一项双盲随机试验,以评估一种Hib结合疫苗预防Hib引起的脑膜炎、肺炎和其他侵袭性疾病的疗效。
1993年3月至1995年10月期间,42848名婴儿在2个月、3个月和4个月大时被随机分配接受与白喉-破伤风-百日咳疫苗(DTP)混合的结合疫苗Hib多糖破伤风蛋白(PRP-T),或仅接受DTP。出现侵袭性Hib体征的儿童通过血培养进行调查,并在适当情况下通过腰椎穿刺、胸部X光片或经皮肺穿刺进行检查。对儿童进行了5至36个月的随访。
儿童接受研究疫苗的中位年龄分别为11周、18周和24周。83%的登记儿童接受了全部三剂疫苗。在研究儿童中检测到17例培养阳性的Hib肺炎、28例Hib脑膜炎和5例其他形式的侵袭性Hib疾病。三剂疫苗后预防所有侵袭性疾病的效力为95%(PRP-T疫苗接种者1例,对照组19例[95%CI 67-100]),两剂或三剂后预防Hib肺炎的效力为100%(疫苗接种者0例,对照组10例[55-100]),登记后任何时间预防放射学确诊肺炎的效力为21.1%(PRP-T疫苗接种者198例,对照组251例[4.6-34.9])。
PRP-T结合Hib疫苗预防了冈比亚婴儿中大多数由Hib引起的脑膜炎和肺炎病例。PRP-T疫苗接种者中放射学确诊肺炎总体发病率的降低表明,冈比亚幼儿约20%的肺炎发作是由Hib引起的。在发展中国家引入Hib疫苗应能大幅降低因肺炎和脑膜炎导致的儿童死亡率。